Article Text

Download PDFPDF
F41 The proof-hd phase 3 study: pridopidine’s outcome on function in huntington disease (PROOF)
  1. Ralf Reilmann1,
  2. Anne Rosser2,
  3. Sandra Kostyk3,
  4. Michal Geva4,
  5. Andrew McGarry5,
  6. Yael Cohen4,
  7. Noga Gershoni-Emek4,
  8. Munish Mehra4,6,
  9. C Warren Olanow5,
  10. Karl Kieburtz5,
  11. Michael R Hayden7,8,
  12. Andrew Feigin9
  1. 1George-Huntington-Institute, Münster, Germany
  2. 2University of Cardiff, Wales, UK
  3. 3The Ohio State University College of Medicine, Ohio, USA
  4. 4Prilenia Neurotherapeutics, Herzeliya, Israel
  5. 5Clintrex LLC, Sarasota, FL, USA
  6. 6Tigermed, Gaithersburg, MD, USA
  7. 7Prilenia Neurotherapeutics, Naarden, the Netherlands
  8. 8Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada
  9. 9NYU Langone Health, Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders, New York, NY, USA

Abstract

Background Pridopidine is a safe, well-tolerated oral drug candidate, that potently activates the Sigma-1 Receptor (S1R). The S1R regulates many cellular processes.. Human brain PET studies show that pridopidine 45 mg bid, the dose evaluated in PROOF, selectively and robustly occupies the S1R.

Total Functional Capacity (TFC) is a validated, regulatory-accepted measure of disease stage and functional decline.

To date, no therapeutic agent has shown benefit on the rate of decline in TFC. Analysis of the pre-specified endpoint TFC in the PRIDE-HD trial shows a beneficial effect of pridopidine 45 mg bid vs. placebo on maintenance of TFC at wk52 (Δ 0.87, p=0.0032). Post-hoc analysis revealed that this effect is driven by early HD patients (TFC 7-13) (Δ 1.16, p=0.0003). The effect remains significant using a more conservative analysis (nominal p=0.016). Responder analysis shows that 45 mg bid reduces the probability of worsening in TFC by 80% (p=0.002,). Exploratory analysis also shows improvements in total motor score, TFC, and the symbol digit modality test vs. placebo (Δ0.6, p=0.04) when assessed in combination. Q-motor, a quantitative motor test, demonstrated improvement in the finger inter-tap interval vs. placebo at wk26 (Δ-0.034 sec, p=0.035) and 52 (Δ-0.044, p=0.03). P-values are nominal.

Aim Evaluate the efficacy and safety of pridopidine 45 mg bid on TFC in early HD.

Design PROOF-HD is a 65-week, double-blind, placebo-controlled, global Ph 3 trial.

PROOF assesses the effect of pridopidine 45 mg bid vs placebo on TFC in early HD patients. Primary endpoint is mean ΔTFC from baseline to Wk 65. Secondary endpoints are the proportion of patients with no TFC decline (TFC≥ 0) at Wk65 and changes from baseline to Wk65 in Q-motor, Total Motor Score (TMS) and cUHDRS.

Status As of July 4, 2021, 58/60 (97%) of sites have been activated and 235 patients have been randomized (48% of the total). There have been no dropouts from the trial, supporting the tolerability and safety of the drug.

  • pridopidine
  • PROOF-HD
  • clinical trial
  • functional capacity

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.